GU Cancers 2026 | Patient-reported outcomes in adjuvant renal cell carcinoma therapy
Sophie Merrick, MBCHB, MRCP, University College London, London, UK, describes the importance of considering patient-reported outcomes when evaluating adjuvant combination therapy in renal cell carcinoma (RCC), highlighting that results from the RAMPART trial (NCT03288532) are forthcoming and will inform the contribution of treatment components. Clinicians need to communicate these outcomes to patients for shared decision making and to consider intensive clinical care, including early and late effects. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the first point to say on that is that adjuvant combination therapy isn’t yet approved. We really need to see the outcomes of the next part of Rampart, which I can tell you that the active surveillance versus durvalumab monotherapy will see the results and patient reported outcomes later this year. So that will inform us about the kind of contribution of components...
I think the first point to say on that is that adjuvant combination therapy isn’t yet approved. We really need to see the outcomes of the next part of Rampart, which I can tell you that the active surveillance versus durvalumab monotherapy will see the results and patient reported outcomes later this year. So that will inform us about the kind of contribution of components. But I think at the moment, this information should be read alongside the efficacy results when we’re thinking about the treatment and the tolerability. And if the treatment were to be licensed, I think this is definitely something we need to communicate with patients for shared decision making and also should be taken into account thinking about clinical care, perhaps more intensive and early check-ins at that early time period and also still considering late effects as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
